ESMO Breast Cancer 2025
Imlunestrant plus abemaciclib improved PFS across subgroups in ER+/HER2- breast cancer, per EMBER-3 data.
Abemaciclib plus fulvestrant showed benefit across biomarkers after CDK4/6i failure in advanced HR+/HER2- breast cancer.
About 40% of patients on AI + palbociclib developed ESR1 mutations in PADA-1, emerging as early as 6 months into treatment.
Zanidatamab plus chemo showed promising responses in HER2+ and HER2-low mBC, with durable activity in a phase I trial.
Dual immunotherapy plus trastuzumab shows activity in ER+ or PD-L1+ trastuzumab-resistant HER2+ breast cancer.
T-DXd improved PFS and response rates vs chemo in HR+/HER2-low or -ultralow metastatic breast cancer in DESTINY-Breast06.
Emiltatug ledadotin showed early clinical activity and was well tolerated in heavily pretreated patients with TNBC.
Ribociclib plus ET shows similar pCR rates to chemo in intermediate-risk HR+/HER2– early breast cancer, per WSG ADAPTcycle.
In-depth coverage of the top stories from the ESMO Breast Cancer 2025 Annual Meeting.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.